Wakely Wire

New Insights

Whitepapers, briefs, press releases and more

Week in Washington 02/27/25

Congress House Republicans voted this week in favor of a budget framework that would require at least $880 billion in Medicaid cuts. The bill does not specify what those cuts are nor does it change current law. It does represent a step towards large Medicaid cuts. Hospital and insurer stocks have reacted negatively to this ... Read more

Continue reading

Newsworthy Findings

Physicians Say Prior Authorization Stands in the Way of Medically Necessary Care

Physicians surveyed by the AMA say that PA can cause care delays or force patients to abandon treatment. They warn denials could increase as insurers adopt AI to review claims.

Read full article
Editor's Note
While AI offers the potential for faster decision-making, it has been shown to deny claims up to 16 times more frequently than human reviewers, raising serious concerns about its negative impact on patient health.

‘Fear and Uncertainty’: Biotech Investors Warn of Impact from NIH Research Cuts

The Trump administration’s plans to reduce National Institutes of Health grant funding could have long-term consequences for the U.S. drug industry, investors said.

Read full article
Editor's Note
Although a federal judge temporarily blocked the policy last Friday following legal challenges from 22 state attorneys general, some biotech investors fear that these funding cuts could slow down research progress.

Substance Use Disorder Screening Must Be Part Of Cancer Care

Substance use disorders (SUDs) in oncology populations represent a significant yet underrecognized challenge, with prior research suggesting that up to 27 percent of cancer patients meet criteria for a SUD and that co-occurring substance misuse can increase annual health care expenditures by thousands of dollars per patient.

Read full article
Editor's Note
This article argues that routine SUD screening in cancer care is essential for both ethical and economic reasons. Early detection and intervention can prevent costly hospitalizations and improve long-term recovery.

Shortage of Novo Nordisk’s Wegovy and Ozempic drugs is resolved, FDA says

The long-running U.S. shortage of Novo Nordisk’s blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years, the U.S. Food and Drug Administration said. The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months, which caused shares of Hims & Hers Health to plunge.

Read full article
Editor's Note
The FDA’s resolution of the Wegovy and Ozempic shortage could significantly impact compounding pharmacies that have been producing cheaper, unbranded versions.

CMS Data: Medicare Advantage Enrollment Growth Hits Skids

Just over 34.4 million people were enrolled in Medicare Advantage (MA) plans as of Feb. 1, representing slim growth across the program's annual enrollment period. Enrollment grew by 3.8% from February 2024 to February 2025, according to anticipated data released this week from the Centers for Medicare & Medicaid Services. This would make for the lowest growth rate in more than a decade, according to researchers at KFF.

Read full article
Editor's Note
Medicare Advantage enrollment saw modest growth at a 3.8% increase from February 2024 to February 2025. This marks the slowest rate in over a decade.

Bonus Article

Just for Fun

Math Joke:

What does a mathematician do when they feel cold?

Prior Week

Q: What does an actuary do when they walk into a bar?

A: Calculate its present value (ā)

Sign up for the
Wakely Wire,

our industry newsletter.